SourceBio International - Full year results ahead of expectations
Anyone trying to accurately predict the intimate vagaries of government covid testing policy is onto a hiding to nothing.
What's far less uncertain however, is that given the NHS’ 6m patient backlog (& climbing) of elective procedures. There’ll be robust demand for the type of healthcare services offered by (SBI ) over the next few years.
Indeed in today's better than expected trading update, the company announced record FY21 results. Posting EBITDA of circa £24.1m (+70% vs £14.2m LY) on sales up 82% to £92.4m. With net cash closing the year strongly too at £33.3m (£8.4m LY), equivalent to 44p/share.
Here the core Healthcare Diagnostics (eg Cellular Pathology testing), Genomics and Stability Storage divisions “are all back to pre-Covid levels, and poised to accelerate their growth”.
Wrt 2022, house broker Liberum anticipating sales & EBITDA to decline to £52.6m & £8.5m respectively due to fewer PCR tests. But with the base business continuing on its long term growth trajectory.
Elsewhere the valuation has been increased from 190p to 205p/share with a BUY rating on the stock.
To me, there continues to be plenty of upside here for patient investors.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.